New HIV-1 Resistance Assays (LiPA) Comparable to Existing Genotype Resistance Tests
go back to news archivesFindings from a recent study concluded that the VERSANT® HIV-1 Resistance Assays (LiPA) produced comparable results to DNA sequencing in correlating the number of active drugs with viral load drops. The study results were presented at the XI International HIV Drug Resistance Workshop in Seville, Spain. The VERSANT® HIV-1 Resistance Assays are line probe assays (LiPA).
Developed and manufactured by Innogenetics, the LiPA technology is a multiprobe strip-based detection system for nucleic acids based on the reverse hybridization principle.
These data are important because they demonstrate that a simple, yet highly efficient test can provide comparable results as the earlier, more complicated sequencing assays. These data also suggest that additional DNA sequence information obtained from the sequencing assays may not provide additional clinical benefit, said Philippe Archinard, CEO of Innogenetics.
Source : Innogenetics N.V. [Belgium]
Now part of Fujirebio Inc View Company Information
Posted on July 10, 2002
LATEST MICROBIOLOGY NEWS
-
Streck Releases Improved ARM-D® Kit, OXA
12 Jun 2025 -
Looking for a Better Alternative to XLT4?
10 Jun 2025
MICROBIOLOGY EVENTS
-
15th Annual Food Sure Summit
15 Jun 2025 -
WaterMicro25
15 Jun 2025 -
Pharmig Europe 2025
17 Jun 2025 -
Combatting Major Food Safety Challenges Through the 4th Industrial Revolution
18 Jun 2025 -
ASM Microbe
19 Jun 2025 -
World's First HPV Genotyping and Normalization Quantification Assay
19 Jun 2025 -
10th Annual Microbiome Movement Summit
23 Jun 2025 -
2025 Endotoxin Testing Summit
24 Jun 2025 -
Introduction to Statistics for Microbiologists
25 Jun 2025 -
Classic and Modern: Integration of Culture Methods and qPCR for Listeria monocytogenes Control
25 Jun 2025